Else Hoibraaten

Nansen Neuroscience Network is a knowledge network focusing on innovation in neurosciences by bringing industry and academia together. Neuroscience is on the threshold of discovering the underlying mechanisms for complex mental and cognitive functions, considered by many to be the most challenging and exciting questions in science. It is also one of the fastest developing areas of medical research, and one in which Norway excels and is making significant contributions. Nansen Neuroscience Network aims to be the driving force in connecting brain science and industry, creating smart solutions for individuals and society and improving quality of life through innovation, research and development of diagnostics, therapeutics and preventive measures.

We are an early stage pharmaceutical development company focused on the development of menaquinone-7 (MQ-7) for the treatment of vascular and other tissue calcification-related diseases. Our Mission: To develop a novel and potentially groundbreaking therapy to help patients prevent and reverse vascular calcification. Vascular calcification and arterial stiffening are a driving factors in MACE (major adverse cardio events) and are implicated in multiple conditions and diseases. There is, as of today, no available therapy to directly address calcification-related arterial stiffness. A recent clinical study stated that end-stage renal disease patients are 50x more likely to suffer from cardiovascular disease than the general population. CKD affects millions of patients across the world, and its occurrence is expected to significantly increase in the coming decades. In aortic stenosis, calcification is often the primary cause or complicating factor. It is an issue affecting millions of patients. Arteriosclerosis is a disease impacting tens of millions of patients, and once again calcification is believed to play a role. In all these diseases, the process of vascular calcification and arterial stiffening is increasingly being recognized as a major factor driving further complications and medical procedures, and putting a burden on healthcare systems likely measured in the billions of dollars. The ability to prevent, and potentially reverse, calcification and arterial stiffening across these various disease conditions would indeed be a game-changing therapy. Kaydence Pharma believes this is possible, and we believe that MQ-7 has the potential to help improve medical outcomes, increase the quality of life and potentially avoid expensive, high-risk procedures for millions of patients.

We are engaged, experienced, direct, operativ and analytical. The company has two partners, Rita Granlund and Geir Julsvoll. Both are state authorised public accountants and former PWC partners. We assist smaller companies in optaining financing. Startup companies often need support from people with the right experience. We can effectively help a new business both on the business side and in ensuring the laws and regulations are being followed. We can help develop a business case that investors understand. With long experience supporting small and big, including listed companies, we can deliver within our fields of competence. We are used to working in teams with our customers, lawyers, banks and other consultants. We will be the extra resource that may contribute to progression and implementation. We may also offer temporary operational support.

Nansen Neuroscience Network is a knowledge network focusing on innovation in neurosciences by bringing industry and academia together. Neuroscience is on the threshold of discovering the underlying mechanisms for complex mental and cognitive functions, considered by many to be the most challenging and exciting questions in science. It is also one of the fastest developing areas of medical research, and one in which Norway excels and is making significant contributions. Nansen Neuroscience Network aims to be the driving force in connecting brain science and industry, creating smart solutions for individuals and society and improving quality of life through innovation, research and development of diagnostics, therapeutics and preventive measures.

We are an early stage pharmaceutical development company focused on the development of menaquinone-7 (MQ-7) for the treatment of vascular and other tissue calcification-related diseases. Our Mission: To develop a novel and potentially groundbreaking therapy to help patients prevent and reverse vascular calcification. Vascular calcification and arterial stiffening are a driving factors in MACE (major adverse cardio events) and are implicated in multiple conditions and diseases. There is, as of today, no available therapy to directly address calcification-related arterial stiffness. A recent clinical study stated that end-stage renal disease patients are 50x more likely to suffer from cardiovascular disease than the general population. CKD affects millions of patients across the world, and its occurrence is expected to significantly increase in the coming decades. In aortic stenosis, calcification is often the primary cause or complicating factor. It is an issue affecting millions of patients. Arteriosclerosis is a disease impacting tens of millions of patients, and once again calcification is believed to play a role. In all these diseases, the process of vascular calcification and arterial stiffening is increasingly being recognized as a major factor driving further complications and medical procedures, and putting a burden on healthcare systems likely measured in the billions of dollars. The ability to prevent, and potentially reverse, calcification and arterial stiffening across these various disease conditions would indeed be a game-changing therapy. Kaydence Pharma believes this is possible, and we believe that MQ-7 has the potential to help improve medical outcomes, increase the quality of life and potentially avoid expensive, high-risk procedures for millions of patients.